S'abonner

Adolescent Suicide Risk Screening: A Secondary Analysis of the SHIELD Randomized Clinical Trial - 01/12/22

Doi : 10.1016/j.jpeds.2022.07.036 
Deepa L. Sekhar, MD, MSc 1, Erich Batra, MD 1, 2, Eric W. Schaefer, MS 3, Leslie R. Walker-Harding, MD 4, Krista L. Pattison, MS 1, Alissa Molinari, MPH 1, Perri Rosen, PhD 5, Jennifer L. Kraschnewski, MD, MPH 1, 3, 6, James G. Waxmonsky, MD 7
1 Department of Pediatrics, Penn State College of Medicine, Hershey, PA 
2 Department of Family and Community Medicine, Penn State College of Medicine, Hershey, PA 
3 Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA 
4 Department of Pediatrics, University of Washington/Seattle Children's, Seattle, WA 
5 Statewide Project Advisor, Garrett Lee Smith Youth Suicide Prevention Grant, Harrisburg, PA 
6 Department of Medicine, Penn State College of Medicine, Hershey, PA 
7 Department of Psychiatry, Penn State College of Medicine, Hershey, PA 

Abstract

Objective

To evaluate the effectiveness of adolescent suicide risk screening to increase initiation of mental health services via a secondary analysis using data from the SHIELD (Screening in High Schools to Identify, Evaluate and Lower Depression) randomized clinical trial, which evaluated school-based screening for major depressive disorder (MDD).

Study design

Students in 14 Pennsylvania high schools were randomized by grade to either the usual school practice of targeted referral for behavior raising a concern for suicide risk or universal screening using the Patient Health Questionnaire-9 (PHQ-9), with any response >0 to item 9 regarding suicide risk considered positive. Students identified in either arm were referred to the Student Assistance Program (SAP), which is mandated in all Pennsylvania schools. The SAP determined follow-up. Study groups were compared using mixed-effects logistic regression.

Results

The participants comprised 12 909 students, with 6473 (50.1%) randomized to universal screening. The study group was 46% female and 43% Hispanic or non-Hispanic Black. Adolescents in the universal screening arm had 7.1-fold greater odds (95% CI, 5.7-8.8) of being identified as at risk for suicide, 7.8-fold greater odds (95% CI, 4.6-13.1) of follow-up needs, and 4.0-fold greater odds (95% CI, 2.0-7.9) of initiating mental health treatment.

Conclusions

Although the PHQ-9 is a MDD screening tool, its use in universal screening increased identification and treatment initiation for adolescents at risk for suicide. This confirms the value of universal screening and suggests that a suicide-specific risk assessment would have even greater impact on treatment initiation for identified youth.

Trial registration

ClinicalTrials.gov: NCT03716869.

Le texte complet de cet article est disponible en PDF.

Keywords : mental health, school-based screening, adolescent suicide

Abbreviations : ASQ, MDD, PHQ-A, PHQ-8, PHQ-9, RCT, SAP, SHIELD, USPSTF


Plan


 The research reported in this publication was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (AD-2017C3-8752).The views presented in this publication are solely the responsibility of the author(s) and do not necessarily represent the views of PCORI, its Board of Governors, or its Methodology Committee. Complementary yet distinct portions of the study are also supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) as part of an award totaling $900 000 (R40MC31765), with 0 percent financed from nongovernmental sources. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the US Government. The use of REDCap (Research Electronic Data Capture) in this project was supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant UL1 TR002014. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Neither PCORI nor HRSA had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. J.W. has received research funding from NIH, Supernus, and Pfizer and consulted for Intracellular Therapeutics and Adlon Pharmaceuticals. J.K. reports grants from PCORI and the Agency for Healthcare Research and Quality during the conduct of the study and grants from Merck outside the submitted work. The other authors declare no conflicts of interest.
 Portions of this study were presented as a virtual live platform research presentation at the 2022 Annual Meeting of the Society for Adolescent Health and Medicine, Mar 10, 2022.


© 2022  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 251

P. 172-177 - décembre 2022 Retour au numéro
Article précédent Article précédent
  • A Diagnostic Prediction Model for Separating Juvenile Idiopathic Arthritis and Chronic Musculoskeletal Pain Syndrome
  • Joeri W. van Straalen, Martine van Stigt Thans, Nico M. Wulffraat, Sytze de Roock, Joost F. Swart
| Article suivant Article suivant
  • Sleep Patterns and School Readiness of Pre-Kindergarteners from Racially and Ethnically Diverse, Low-Income Backgrounds
  • Khara L.P. Turnbull, Deiby Mayaris Cubides Mateus, Jennifer LoCasale-Crouch, Daniel S. Lewin, Amanda P. Williford

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.